Trial
NCT01379469
Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Novartis; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Condition
Alpha-1-antitrypsin Deficiency
Intervention
Drug-Carbamazepine (Tegretol XR)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-12